TY  - JOUR
AU  - Hirschberg, Angelica Lindén
AU  - Sánchez-Rovira, Pedro
AU  - Presa-Lorite, Jesús
AU  - Campos-Delgado, Miriam
AU  - Gil-Gil, Miguel
AU  - Lidbrink, Elisabet
AU  - Suárez-Almarza, Javier
AU  - Nieto-Magro, Concepción
PY  - 2020
DO  - 10.1097/GME.0000000000001497
UR  - http://hdl.handle.net/10668/15093
T2  - Menopause (New York, N.Y.)
AB  - To assess the efficacy and safety of ultra-low dose 0.005% estriol vaginal gel in women with breast cancer receiving nonsteroidal aromatase inhibitors (NSAIs) and experiencing treatment-related vulvovaginal symptoms and signs. Women with hormone...
LA  - en
KW  - Administration, Intravaginal
KW  - Aromatase Inhibitors
KW  - Atrophy
KW  - Breast Neoplasms
KW  - Estriol
KW  - Estrogens
KW  - Female
KW  - Humans
KW  - Middle Aged
KW  - Postmenopause
KW  - Treatment Outcome
KW  - Vagina
KW  - Vaginal Creams, Foams, and Jellies
TI  - Efficacy and safety of ultra-low dose 0.005% estriol vaginal gel for the treatment of vulvovaginal atrophy in postmenopausal women with early breast cancer treated with nonsteroidal aromatase inhibitors: a phase II, randomized, double-blind, placebo-controlled trial.
TY  - research article
VL  - 27
ER  -